These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 28389353

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C.
    Younossi ZM, Park H, Gordon SC, Ferguson JR, Ahmed A, Dieterich D, Saab S.
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP205-11. PubMed ID: 27266950
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV.
    Tadokoro T, Morishita A, Fujita K, Oura K, Sakamoto T, Nomura T, Tani J, Yoneyama H, Masaki T.
    Intern Med; 2018 Apr 15; 57(8):1101-1104. PubMed ID: 29279506
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Moser S, Kozbial K, Laferl H, Schütz A, Reiberger T, Schwabl P, Gutic E, Schwanke C, Schubert R, Luhn J, Lang T, Schleicher M, Steindl-Munda P, Haltmayer H, Ferenci P, Gschwantler M.
    Eur J Gastroenterol Hepatol; 2018 Mar 15; 30(3):291-295. PubMed ID: 29120906
    [Abstract] [Full Text] [Related]

  • 10. Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass.
    Johnson SW, Teachey AL, Valanejad SM, Griffin SM, Weber SF.
    J Clin Pharm Ther; 2017 Oct 15; 42(5):624-626. PubMed ID: 28474386
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
    Elfeki MA, Abou Mrad R, Modaresi Esfeh J, Zein NN, Eghtesad B, Zervos X, Hanouneh IA, O'Shea R, Carey WD, Alkhouri N.
    Transplantation; 2017 May 15; 101(5):996-1000. PubMed ID: 27631598
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
    Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, McHutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, Sulkowski M.
    Hepatology; 2015 Jul 15; 62(1):25-30. PubMed ID: 25963890
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D, Pockros P, Morelli G, Younes Z, Svarovskaia E, Yang JC, Pang PS, Zhu Y, McHutchison JG, Flamm S, Lawitz E.
    Hepatology; 2015 Jun 15; 61(6):1793-7. PubMed ID: 25846014
    [Abstract] [Full Text] [Related]

  • 20. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.
    Latt NL, Yanny BT, Gharibian D, Gevorkyan R, Sahota AK.
    World J Gastroenterol; 2017 Jul 14; 23(26):4759-4766. PubMed ID: 28765697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.